Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 23 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research.
- 20 Aug 2018 Status changed from not yet recruiting to recruiting.